SELEX技术在胰腺癌分子诊断及靶向治疗中应用的研究进展

胰腺癌由于起病隐匿,早期诊断率较低,临床治疗效果差,是目前预后最差的恶性肿瘤之一。目前,临床上尚缺乏有效的非创伤早期筛查胰腺癌的手段,因而胰腺癌的早期诊断和治疗显得尤为重要。近年来,指数富集配基的系统进化(SELEX)技术以其在其他疾病中所表现的应用价值为疾病的诊治提供了一个新的途径。对于缺乏有效确诊手段,发病隐匿且病死率高的胰腺癌而言,SELEX技术基于胰腺癌发病的分子机制,可以筛选出特异结合于胰腺癌分子靶标的适配体,对筛选所得适配体进一步化学修饰,可以实现分子水平成像及靶向治疗,进而达到胰腺癌早期诊治的目的,具有重要的临床意义。本文就SELEX技术在胰腺癌分子诊断及靶向治疗中的应用研究进展进行了综述。

Research Progress of the Application of SELEX Technology in MolecularDiagnostics and Targeted Therapy of Pancreatic Cancer*

Pancreatic cancer is one of the most poor prognosis tumors. A primary cause for this is that pancreatic adenocarcinomahas no noticeable sign or symptoms at the early stage, and no effective medicine has been found for the tumor yet. At present, there is nosuitable examination to screen pancreatic cancer at the early stage without injury. So, it is very important to find methods for the early diagnosisand treatment of pancreatic cancer. In recent years, SELEX(systematic evolution of ligands by exponential enrichment) technologyhas provided a new method for the early diagnosis of pancreatic cancer on the basis of valuable applications in other cancers. This technologycan screen aptamers which specificly bind to molecular targets of the pancreatic cancer for the pathogenesis. Then, the furtherchemical modification for those aptamers may turn the target, molecular level imaging, early diagnosis, targeted therapy and early treatment,to be true. This has a great significance. This article will review the progress and application of SELEX technology in molecular diagnosisand targeted therapy of pancreatic cancer.